News about Global Pharma

Aurora Pharmaceutical Announces Availability of EquiCoxib

Aurora Pharmaceutical announced the availability of EquiCoxib, the FDA-approved generic equivalent of Equioxx® (firocoxib), a non-steroidal anti-inflammatory drug (NSAID) used for pain and inflammation associated with osteoarthritis.

Global Pharma | 14/02/2025 | By Manvi |  339

Akeso Announces IND Acceptance for AK139

Akeso, Inc. announces the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα and ST2. AK139 is under investigation for a number of indications, including respiratory and skin diseases.

Global Pharma | 14/02/2025 | By Manvi |  687

Tillotts Pharma AG Celebrates 15 Years Anniversary as Part of Japanese Zeria Group

This commitment has also led to Tillotts in-licensing the product Dificlir™ for the treatment of Clostridioides difficile infection (CDI) in 2020, a potentially life-threatening disease.

Global Pharma | 14/02/2025 | By Aishwarya |  379

Clinigen and Essential Pharma to Improve Patient Access in JAPAC

IOPIDINE 5mg/ml is a short-term adjunctive therapy for patients with chronic glaucoma on maximally tolerated medical therapy to prevent or control intraocular pressure.

Global Pharma | 14/02/2025 | By Aishwarya |  577

JuliaHub Doubles Investment in Advanced Pharmaceutical Modeling Platform

JuliaHub simplifies complex pharmaceutical workflows by integrating analytics such as modeling and simulation in pharmacometrics.

Global Pharma | 14/02/2025 | By Aishwarya |  687

Antengene Announces XPOVIO Approved for Public Health Insurance Coverage in Taiwan Market

With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in nine countries and regions in APAC, and included in the public insurance schemes in five of those markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea).

Global Pharma | 13/02/2025 | By Manvi |  726

Burkert Fluid Control Systems Acquires Stake in Green Elephant Biotech

The partnership gives Bürkert access to the latest trends and developments in the biopharmaceutical industry, one of the strategic core markets of the fluidics specialist from Ingelfingen.

Global Pharma | 13/02/2025 | By Aishwarya |  602

Royalty Pharma Signs R&D Funding Agreement with Biogen

Litifilimab is currently in Phase 3 trials for both SLE and CLE with results expected between 2026 and 2027.

Global Pharma | 13/02/2025 | By Aishwarya |  280

Zydus and Synthon to Commercialise Novel 505(B)(2) Oncology Product in US

Under the terms of this agreement, Synthon will be responsible for the development, manufacturing and supply of the finished product.

Global Pharma | 13/02/2025 | By Aishwarya |  571

Oramed to Accelerate Development and Commercialization of Oral Insulin

As part of the transaction, Oramed will transfer its proprietary oral insulin and POD™ technology, along with other pipeline assets, into OraTech.

Global Pharma | 13/02/2025 | By Aishwarya |  391